ITUA20161967A1 - Sensibilizzazione di cellule cancerose a inibitori di NAMPT mediante neutralizzazione di acido nicotinico fosforibosiltransferasi - Google Patents

Sensibilizzazione di cellule cancerose a inibitori di NAMPT mediante neutralizzazione di acido nicotinico fosforibosiltransferasi

Info

Publication number
ITUA20161967A1
ITUA20161967A1 ITUA2016A001967A ITUA20161967A ITUA20161967A1 IT UA20161967 A1 ITUA20161967 A1 IT UA20161967A1 IT UA2016A001967 A ITUA2016A001967 A IT UA2016A001967A IT UA20161967 A ITUA20161967 A IT UA20161967A IT UA20161967 A1 ITUA20161967 A1 IT UA20161967A1
Authority
IT
Italy
Prior art keywords
sensitization
neutralization
cancer cells
nicotinic acid
nampt inhibitors
Prior art date
Application number
ITUA2016A001967A
Other languages
English (en)
Inventor
Alessio Nencioni
Francesco Piacente
Irene Caffa
Michel Duchosal
Aimable Nahimana
Original Assignee
Univ Degli Studi Genova
Centre Hospitalier Univ Vaudois Chuv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Genova, Centre Hospitalier Univ Vaudois Chuv filed Critical Univ Degli Studi Genova
Priority to ITUA2016A001967A priority Critical patent/ITUA20161967A1/it
Priority to PCT/EP2017/057021 priority patent/WO2017162840A1/en
Publication of ITUA20161967A1 publication Critical patent/ITUA20161967A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ITUA2016A001967A 2016-03-24 2016-03-24 Sensibilizzazione di cellule cancerose a inibitori di NAMPT mediante neutralizzazione di acido nicotinico fosforibosiltransferasi ITUA20161967A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITUA2016A001967A ITUA20161967A1 (it) 2016-03-24 2016-03-24 Sensibilizzazione di cellule cancerose a inibitori di NAMPT mediante neutralizzazione di acido nicotinico fosforibosiltransferasi
PCT/EP2017/057021 WO2017162840A1 (en) 2016-03-24 2017-03-23 Sensitization of cancer cells to nampt inhibitors by nicotinic acid phosphoribosyltransferase neutralization

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A001967A ITUA20161967A1 (it) 2016-03-24 2016-03-24 Sensibilizzazione di cellule cancerose a inibitori di NAMPT mediante neutralizzazione di acido nicotinico fosforibosiltransferasi

Publications (1)

Publication Number Publication Date
ITUA20161967A1 true ITUA20161967A1 (it) 2017-09-24

Family

ID=56235880

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUA2016A001967A ITUA20161967A1 (it) 2016-03-24 2016-03-24 Sensibilizzazione di cellule cancerose a inibitori di NAMPT mediante neutralizzazione di acido nicotinico fosforibosiltransferasi

Country Status (2)

Country Link
IT (1) ITUA20161967A1 (it)
WO (1) WO2017162840A1 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087199A1 (en) * 2017-11-06 2019-05-09 Curewize Health Ltd. Methods for prognosis and treatment of solid tumors
JP2019137638A (ja) * 2018-02-09 2019-08-22 アピオン・ジャパン有限会社 新規ｎａｍｐｔ阻害剤およびそれを含有する抗腫瘍剤、新規ｎａｍｐｔ阻害剤のスクリーニング方法、新規ｎａｐｒｔ阻害剤およびそれを含有する抗腫瘍剤、新規ｎａｐｒｔ阻害剤のスクリーニング方法、腫瘍細胞に対して正常細胞の割合を増やすための方法、並びに抗腫瘍剤の処方を補助する方法
CN116010663B (zh) * 2023-03-21 2023-06-30 上海美吉生物医药科技有限公司 一种tmt项目图谱解析和数据分析的方法及系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006988A1 (en) * 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006988A1 (en) * 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNE ROULSTON ET AL: "New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology", MOLECULAR & CELLULAR ONCOLOGY, vol. 3, no. 1, 10 June 2015 (2015-06-10), pages e1052180, XP055327016, DOI: 10.1080/23723556.2015.1052180 *
D. S. SHAMES ET AL: "Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors", CLINICAL CANCER RESEARCH, vol. 19, no. 24, 4 October 2013 (2013-10-04), US, pages 6912 - 6923, XP055326877, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-1186 *
GAUT Z N ET AL: "Inhibition of 7-<14>C nicotinic acid metabolism in the human blood platelet by anti inflammatory drugs", RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, PJD PUBLICATIONS LTD., WESTBURY, NY, US, vol. 1, no. 4, 1 July 1970 (1970-07-01), pages 547 (22) - 552 (29), XP008182522, ISSN: 0034-5164 *
GAUT Z N ET AL: "Inhibition of nicotinate phosphoribosyltransferase in human platelet lysate by nicotinic acid analogs", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 20, no. 10, 1 October 1971 (1971-10-01), pages 2903 - 2906, XP025541799, ISSN: 0006-2952, [retrieved on 19711001], DOI: 10.1016/0006-2952(71)90202-4 *

Also Published As

Publication number Publication date
WO2017162840A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
HK1244440A1 (zh) 癌症對通過pd-1阻斷實現的免疫療法響應的決定因素
ZA201803436B (en) Inhibitors of cxcr2
HK1245242A1 (zh) 丙烯酸生產方法
DK3932951T3 (da) Fremgangsmåder til behandling af hudcancer ved administration af en PD-1-hæmmer
DK3332019T3 (da) Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
DK3145420T3 (da) Intraoperativ fremgangsmåde til tracking
DK3261721T3 (da) Anvendelse af pridopidin til forbedring af hukommelse
DK3831833T3 (da) Fremgangsmåder til fremstillingen af en pi3k-inhibitor
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
ITUA20161967A1 (it) Sensibilizzazione di cellule cancerose a inibitori di NAMPT mediante neutralizzazione di acido nicotinico fosforibosiltransferasi
DK3445743T3 (da) Prodrug af aminosyrederivat
ZA201706399B (en) Field application of sugars to increase crop yield
DK3242955T3 (da) Modelering af ribosom-dynamikker til at optimere heterolog proteinproduktion
DK3248967T3 (da) Krystallinsk form af et benzimidazolderivat og en fremstillingsfremgangsmåde herfor
FI20155412A (fi) Sokerien suora konversio glykolihapoksi
DK2845844T3 (da) Modulært anlæg til fremstilling af et forstadium for en eksplosiv emulsion
ITUB20153414A1 (it) Matrici di nicchioidi sintetiche per la coltivazione di cellule staminali
ITUB20153490A1 (it) Miscele di esteri dell?acido pelargonico
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
FR3004002B1 (fr) Procede d&#39;assemblage avance de cellule photovoltaique concentree
FI20155387A (fi) Sterolien tuottaminen
FR3006314B1 (fr) Nouveau procede de synthese de derives n-alkyl-glycosyl(di)amine et leurs applications
IT201700104587A1 (it) Usi terapeutici di lembi di cellule geneticamente modificate
HK1214596A1 (zh) 經取代噻唑基乙酸三乙胺鹽的結晶型
FR3010227B1 (fr) Procede de formation d&#39;une cellule photovoltaique